[HTML][HTML] Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - Springer
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
[PDF][PDF] Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - core.ac.uk
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
[PDF][PDF] Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - 2014 - researchgate.net
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
Anti-angiogenic therapy for cancer: Current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - eprints.whiterose.ac.uk
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - pubmed.ncbi.nlm.nih.gov
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
[引用][C] Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - cir.nii.ac.jp
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future
directions | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
directions | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …
[PDF][PDF] Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - academia.edu
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - infona.pl
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
[HTML][HTML] Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - ncbi.nlm.nih.gov
Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …
angiogenic growth factors, including members of the vascular endothelial growth factor …
[引用][C] Erratum to: Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
NS Vasudev, AR Reynolds - Angiogenesis, 2014 - Springer
Colorectal cancer Metastatic 1st line IFL±bevacizumab AVF2107 [19] Improvement in OS
and PFS FOLFOX or XELOX±bevacizumab NO16966 [21] Improvement in PFS …
and PFS FOLFOX or XELOX±bevacizumab NO16966 [21] Improvement in PFS …